Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649062 · ClinicalTrials.gov registry record · Phase 1
Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals
A Phase 1 study of Functional Constipation, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT02649062: Completed Phase 1 study of Functional Constipation, sponsored by NGM Biopharmaceuticals.
NCT02649062 is a Phase 1 study of Functional Constipation that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 31 participants, below the 134-participant average among 4 other Functional Constipation trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02649062, a Phase 1 study of Functional Constipation, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect of NGM282 on colonic transit, bile acid homeostasis, and fecal fat in subjects with functional constipation and healthy individuals.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL NGM282
Study Locations (1)
Minnesota
- NGM Clinical Study Site 1 - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
What the finished NCT02649062 record still lists
NCT02649062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 134-participant average among 4 other Functional Constipation trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Functional Constipation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02649062 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02649062 about?
NCT02649062 is a clinical study titled "Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals". The purpose of this study is to determine the effect of NGM282 on colonic transit, bile acid homeostasis, and fecal fat in subjects with functional constipation and healthy individuals.
What is the current status of trial NCT02649062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2015-12. Estimated completion is 2017-01.
What conditions does trial NCT02649062 study?
This clinical trial studies the following conditions: Functional Constipation.
What interventions are being tested in trial NCT02649062?
The interventions under investigation include: Placebo (OTHER), NGM282 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02649062?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02649062 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Functional Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation
COMPLETED · Phase 1
-
A Study of Herbal Supplements in Cancer Survivors With Constipation
RECRUITING · NA
-
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
COMPLETED · Phase 3
-
Adherence and Outcomes in Functional Constipation With a Constipation Action Plan
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia